Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RAD140 |
Synonyms | |
Therapy Description |
RAD140 is a selective androgen receptor modulator that results in AR agonist activity, which potentially leads to the regulation of AR target genes, repression of Esr1, and inhibition of tumor growth (PMID: 28974548). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RAD140 | RAD-140|RAD 140|EP0062|EP 0062|EP-0062|Vosilasarm | Hormone - Anti-androgens 54 | RAD140 is a selective androgen receptor modulator that results in AR agonist activity, which potentially leads to the regulation of AR target genes, repression of Esr1, and inhibition of tumor growth (PMID: 28974548). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03088527 | Phase I | RAD140 | Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer | Completed | USA | 0 |
NCT05573126 | Phase Ib/II | RAD140 | Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer | Recruiting | USA | GBR | ESP | 0 |